Dr Eric Jonasch, of the University of Texas MD Anderson Cancer Center, highlights studies in renal cell carcinoma (RCC) presented at the ASCO 2021 Annual Meeting.
Dr Jonasch first reports on the late-breaking KEYNOTE-564 study, the first positive phase 3 study of adjuvant immunotherapy in RCC. Pembrolizumab may offer a potential new standard of care, demonstrating a 32% reduction in the risk for recurrence or death compared with placebo.
Next, he comments on the health-related quality-of-life update from the CLEAR trial, which seems to further support lenvatinib in combination with pembrolizumab as first-line therapy for patients with advanced RCC.
Finally, Dr Jonasch reports exciting results for hard-to-treat cases, including treatment for variant histology and management of patients with brain metastases, who are usually excluded from RCC trials.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Highlights in Renal Cell Carcinoma From ASCO 2021 - Medscape - Jun 25, 2021.
Comments